Welcome to our dedicated page for MTSR news (Ticker: MTSR), a resource for investors and traders seeking the latest updates and insights on MTSR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MTSR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MTSR's position in the market.
Metsera (Nasdaq: MTSR), a clinical-stage biotech company focused on developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides for obesity treatment, has announced the pricing of its initial public offering. The company is offering 15,277,778 shares of common stock at $18.00 per share, expecting to raise gross proceeds of approximately $275.0 million before deducting underwriting costs and expenses.
Trading is set to begin on the Nasdaq Global Select Market under ticker 'MTSR' on January 31, 2025, with the offering expected to close on February 3, 2025. Metsera has granted underwriters a 30-day option to purchase up to an additional 2,291,666 shares at the IPO price. BofA Securities, Goldman Sachs, Evercore ISI, Guggenheim Securities, and Cantor are serving as joint bookrunners.
